EU MDR Delays: What US Device Exporters Need to Know

Every time the European Union pushes back a Medical Device Regulation deadline, I get the same question from US clients: does this mean we have more time, or less? The honest answer is both. The extensions bought the market more runway, but they also added conditions that quietly disqualify manufacturers who treat "extended" as "solved." If you export devices into the EU, or you're planning to, the deadline math matters less than understanding which door just got narrower.

EU MDR (Regulation (EU) 2017/745) has never actually arrived on schedule. It was adopted in 2017 with a planned application date of 26 May 2020. COVID-19 pushed that to 26 May 2021 under Regulation (EU) 2020/561. Then, as the original transition deadlines for legacy devices approached in 2024, the European Commission concluded that notified body capacity simply wasn't there to recertify the volume of devices still operating under the old Medical Device Directive. So it delayed again — this time through Regulation (EU) 2023/607, adopted 15 March 2023. That's the amendment every US exporter needs to understand, because it's the one currently governing whether your device can stay on EU shelves.

A Regulation That Keeps Moving Its Own Deadline

The pattern is worth naming plainly: MDR has been delayed twice in five years, and both delays trace back to the same root cause — insufficient notified body capacity relative to the number of devices requiring conformity assessment. The 2020 delay was framed as a pandemic accommodation. The 2023 delay was not. The recitals to Regulation (EU) 2023/607 state directly that without intervention, a shortage of certified capacity risked device shortages across the EU market, including devices with no MDR-certified alternative available. That's a regulator admitting its own system couldn't process the backlog it created. It's a useful thing to know, because it tells you the delay isn't a courtesy. It's damage control, and damage control comes with strings attached.

Those strings are what trip up US exporters who read the extended deadline and stop reading.

What Regulation (EU) 2023/607 Actually Changed

The amendment replaced a single hard transition deadline with a risk-based staircase. Higher-risk devices get less extra time; lower-risk devices get more. The table below reflects the deadlines set out in amended MDR Article 120(3c).

Two things in that table deserve emphasis because they're the parts I see missed most often.

First, the extension is not automatic. A manufacturer had to have its quality management system aligned with MDR's Article 10(9) requirements and had to have already lodged a conformity assessment application with a notified body by 26 May 2024 to qualify for the Class III and implantable Class IIb pathway. If that application wasn't filed, the extension doesn't apply, full stop.

Second, the sell-off deadline is gone. Regulation (EU) 2023/607 eliminated the "sell-off" deadline entirely for devices already placed on the market before their applicable transition date — previously set at 27 May 2025 under the original MDR text. Devices that made it onto the market in time can now keep being distributed without an expiration date on availability, as long as they continue to meet the older MDD or AIMDD requirements they were certified against.

Why This Keeps Happening: The Notified Body Bottleneck

Under the old Medical Device Directive, a much larger and more loosely supervised pool of notified bodies handled conformity assessments. MDR raised the technical and staffing bar for notified body designation substantially, and the European Commission's own NANDO database reflects a much smaller pool of MDR-designated bodies competing to process a device population that hadn't shrunk to match.

MDCG 2022-11, the Medical Device Coordination Group's "Notice to manufacturers to ensure timely compliance with MDR requirements," published in June 2022 and updated in November 2023, laid out the capacity math that led directly to the 2023 amendment: manufacturers who hadn't already engaged a notified body were told, in effect, to get in line immediately or risk missing the extension altogether.

That bottleneck hasn't disappeared with the new deadlines. It's been pushed to 2027 and 2028. A US manufacturer that waits until 2026 to start the notified body conversation is repeating the exact mistake that forced this amendment in the first place, just on a longer fuse.

What This Means for US Medical Device Exporters

FDA clearance does not open the EU market, and CE marking under MDR does not open the US market. They are separate systems built around different questions — the FDA asks whether a device is safe and effective for its indication; MDR's conformity assessment asks whether a device meets the EU's General Safety and Performance Requirements set out in Annex I. A device with an active 510(k) or PMA has done none of the EU's paperwork, and vice versa. The practical consequence for a US manufacturer is that MDR compliance is a parallel build, not a byproduct of FDA clearance.

Three MDR obligations apply specifically because a manufacturer sits outside the EU:

Authorized Representative (Article 11). Any manufacturer without a registered place of business in the EU must appoint a single EU Authorized Representative before a device can carry the CE mark. The Authorized Representative is not a mailbox service — Article 11(3) makes it jointly and severally liable for defective devices alongside the manufacturer, which is why the mandate agreement between the two parties matters as much as the appointment itself.

Person Responsible for Regulatory Compliance, or PRRC (Article 15). Every manufacturer needs at least one PRRC with defined qualifications in regulatory affairs or quality management. A US manufacturer without EU-based staff doesn't independently contract out its own PRRC — under Article 15(6), it's the manufacturer's Authorized Representative that is required to have a PRRC available, which is one more reason the AR mandate agreement carries real operational weight rather than just formal appointment.

Technical documentation aligned to Annexes II and III, not to a 510(k) submission binder. FDA and MDR technical files overlap in substance (device description, risk management, clinical evaluation) but differ enough in structure and required content that a straight copy-paste from an FDA submission routinely fails an MDR technical documentation review.

Here's a side-by-side of the obligations that catch US exporters off guard most often:

The QMS row is the one place these systems already converge, which is exactly why a manufacturer with a mature ISO 13485:2016 system has a real head start on MDR readiness rather than starting from zero.

The Compliance Traps Hiding Inside "Extended" Deadlines

Three failure modes show up repeatedly in manufacturers who assumed the extension was a blanket reprieve.

The first is design freeze violation. The extended transition under Article 120(3) only protects a device whose design and intended purpose haven't changed since its original MDD or AIMDD certification. A labeling update to reflect a new indication, a materials substitution, or a software update that changes intended use can all be read as a "significant change" that forfeits the extension and forces the device into full MDR conformity assessment immediately — with none of the extra runway.

The second is the missed procedural gate. The Class III and implantable Class IIb extension required a conformity assessment application lodged by 26 May 2024. That date has already passed. If your organization didn't file, the 2027 deadline isn't available to you for that device family, regardless of how compliant your quality system is otherwise.

The third is EUDAMED drift. MDR Articles 33 and 34 establish the European Database on Medical Devices, and while full mandatory use has been staged out over several years, registration obligations for actor registration, device (UDI/basic UDI-DI) data, and certificates have been phasing in on separate tracks. A manufacturer that's current on notified body certification but hasn't kept its EUDAMED actor and device registrations current can still find its devices flagged in market surveillance checks.

A Practical Sequence for US Exporters

I generally walk clients through the same sequence, regardless of device class, because the order matters more than the individual steps:

1. Confirm your device's actual transition status. Don't assume. Pull the notified body certificate, check the class, and confirm whether an MDR conformity assessment application was lodged before the relevant 2024 deadline.
2. Audit your QMS against ISO 13485:2016, not just against 21 CFR Part 820. MDR requires a QMS "in accordance with Article 10(9)," and the fastest route to demonstrating that is a genuine ISO 13485 system, not a QSR system with an MDR label pasted on.
3. Appoint (or re-verify) your EU Authorized Representative and PRRC. If these appointments predate 2023, confirm the mandate agreements reflect current liability language under Article 11(3).
4. Engage a notified body early, even for devices with extended deadlines. The capacity shortage that caused this entire round of delays hasn't resolved; it's just been pushed further down the calendar.
5. Reconcile EUDAMED registrations for actors, devices, and certificates against what's actually been submitted, not what you believe was submitted.

None of these steps are exotic. What sinks US exporters is sequencing — treating the extended deadline as permission to defer the QMS work, when the QMS work is the actual gate to using the extension in the first place.

Frequently Asked Questions

Does the EU MDR extension mean my device can wait until 2027 or 2028 to comply? Only if it already qualifies for the extension under Regulation (EU) 2023/607 — meaning the device had a valid MDD/AIMDD certificate, a compliant QMS was in place, and the required conformity assessment application or notified body agreement was filed by the 2024 deadlines. New devices and devices with lapsed certificates don't get the extension.

Do US manufacturers need a separate EU Authorized Representative for every device, or one for the company? MDR Article 11 requires one Authorized Representative mandate, which can cover multiple devices from the same manufacturer, but the mandate agreement must specifically identify the devices it covers and the manufacturer remains jointly liable for each of them.

Can a device change its labeling or indications and keep its extended MDR transition deadline? Generally no. Article 120(3) ties the extension to the device remaining unchanged in design and intended purpose. A significant modification typically forfeits the extension and requires full MDR conformity assessment before the device can continue being placed on the market.

Is IVDR on the same delayed timeline as MDR? No — IVDR (Regulation (EU) 2017/746) runs on its own schedule, originally set to apply from 26 May 2022, with its own separate transition extensions introduced by Regulation (EU) 2022/112. In vitro diagnostic manufacturers need to check IVDR deadlines independently rather than assuming MDR dates apply.

What happens if a US exporter's notified body application was never filed by the 2024 deadline? The device loses eligibility for the extended transition period and must either complete full MDR conformity assessment on an accelerated basis or exit the EU market until certification is obtained. There's no further grace period built into the current regulation for missed 2024 filings.

An EU MDR strategy that's built around ISO 13485:2016 alignment tends to survive the next regulatory shift better than one built purely around meeting whatever deadline happens to be current, because the QMS is the thing every version of this regulation keeps coming back to. If you're assessing where your quality system actually stands against that standard, that's a conversation worth having before the next notified body backlog forces the timeline for you. Certify Consulting's ISO 13485 consulting services work through that gap analysis directly, and you can reach out here to start one.

Last updated: 2026-09-02